Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
p38αMAPK Inhibitor
MW108 hydrochloride is a selective inhibitor of p38α MAPK, with an affinity (Ki) of 114 nM. This compound demonstrates the ability to mitigate beta-amyloid-induced synaptic impairments and cognitive dysfunction, making it a valuable tool for studying neurodegenerative disorders. Its central nervous system penetration enhances its utility in research focused on Alzheimer's disease and related pathologies. -
p38α-MK2 Inhibitor
p38α-MK2-IN-1 is a potent inhibitor of the p38α-MK2 complex, demonstrating an IC50 of 5 nM. This compound exhibits significant anti-inflammatory properties and promotes joint repair, making it a valuable tool for studies focused on inflammation and regenerative medicine. Researchers can employ p38α-MK2-IN-1 in various applications, including drug discovery and the exploration of signaling pathways related to inflammatory responses. -
p38 Kinase Inhibitor
p38 Kinase-IN-9 is a potent p38 kinase inhibitor characterized by an IC50 of less than 1 μM. This compound is valuable for investigating the role of p38 kinase in various diseases, particularly those related to inflammation. It serves as a useful tool for research applications aimed at understanding the mechanistic pathways of p38-mediated disorders. -
p38α Inhibitor
p38α-IN-9 is a potent p38α inhibitor that effectively suppresses the enzymatic activity of p38α with an IC50 value below 20 nM. This compound inhibits MK2T334 phosphorylation, resulting in the activation of Cdc25b and Cdc25c, while concurrently inactivating Wee1. The modulation of these pathways induces mitotic catastrophe, aneuploidy, and polyploidy, contributing to DNA damage. p38α-IN-9 is particularly relevant in studies of colorectal cancer metastasis. -
p38 MAPK Inhibitor
(aS)-PH-797804 is a selective inhibitor of p38 MAPK, demonstrating IC50 values of 26 nM for p38 α and 102 nM for p38 β. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research applications focused on inflammatory signaling pathways and related disease models. Its specificity towards p38 MAPK allows for the exploration of its role in cellular processes and therapeutic interventions in conditions associated with p38 MAPK dysregulation. -
p38α Inhibitor
p38α inhibitor 3 is a selective p38α inhibitor that impedes myoblast differentiation. By targeting the p38 MAPK pathway, this compound plays a crucial role in modulating cellular responses associated with inflammation and stress. Its applications include studying muscle development and cellular signaling processes in various research contexts. -
p38 MAP Kinase Inhibitor
p38 MAP Kinase-IN-2 is a potent inhibitor of the p38 MAP Kinase pathway, primarily involved in cellular stress responses and inflammation. This compound demonstrates significant inhibitory activity, making it valuable for cancer research and the investigation of various inflammatory diseases. Its mechanism and efficacy provide a useful tool for studying the role of p38 MAP Kinase in cellular processes and therapeutic applications. -
p38 MAPK Inhibitor
RPR-200765A methanesulfonate is a potent inhibitor of p38 MAPK, demonstrating an IC50 of 0.050 μM. This compound selectively targets the p38 MAPK pathway while showing minimal activity against Lck, ERK, ZAP70, and SYK. RPR-200765A methanesulfonate effectively inhibits TNFα production, making it a valuable tool for investigating inflammatory diseases and related cellular processes. -
p38α MAP Kinase Inhibitor
BMS-626531 is a selective inhibitor of p38α MAP kinase, demonstrating potent activity against this important signaling pathway. This compound has been shown to effectively modulate cellular responses associated with inflammation and stress, making it a valuable tool in cancer research. Its ability to inhibit p38α MAP kinase renders it useful for investigating mechanisms of tumor progression and potential therapeutic applications in oncology. -
p38 MAPK Inhibitor
p38-α MAPK-IN-6 is a selective inhibitor of the p38α mitogen-activated protein kinase (MAPK). This compound modulates inflammatory responses by inhibiting the activation of p38 MAPK, a key regulator in cellular stress signaling pathways. It is useful in research applications focused on studying inflammatory diseases, neurodegeneration, and cancer biology. -
p38 MAPK Inhibitor
Macranthoin G is a selective inhibitor of p38 MAPK, a critical signaling pathway involved in stress responses. This compound demonstrates protective effects against cytotoxicity induced by amyloid-beta (Aβ) and hydrogen peroxide in neuronal cells by downregulating p38 MAPK activity. Macranthoin G is a valuable tool for research applications related to neurodegenerative diseases, particularly Alzheimer’s Disease. -
p38 MAPK Inhibitor
p38 MAPK-IN-8 is a potent and selective inhibitor of p38 mitogen-activated protein kinase (p38 MAPK). It exhibits strong oral bioavailability, making it an ideal candidate for in vivo studies. This compound is valuable for investigating inflammatory responses, autoimmune disorders, and various cancer pathways, facilitating a deeper understanding of these complex biological processes. -
p38α MAPK/BChE Inhibitor
ARRY-371797 is a potent and orally bioavailable inhibitor of p38α MAPK and butyrylcholinesterase (BChE), demonstrating IC50 values of 12.0 µM for p38α MAPK and 0.13 µM for BChE, with minimal activity against human acetylcholinesterase (hAChE). This compound shows promise for research applications in Alzheimer’s disease, particularly in the context of neuroinflammation and cholinergic system modulation. -
p38 MAP Kinase Inhibitor
p38 MAPK-IN-7 is a selective inhibitor of p38 MAP kinase, exhibiting an IC50 value of 170 nM. This compound demonstrates potent inhibition of p38 MAPK activity, making it a valuable tool for investigating the role of this kinase in various inflammatory diseases, including rheumatoid arthritis and septic shock. Its oral bioavailability enhances its potential for in vivo studies aimed at understanding the therapeutic implications of p38 MAPK modulation. -
p38α Mitogen-Activated Protein Kinase Inhibitor
R 1487 is a highly selective inhibitor of the p38α mitogen-activated protein kinase. It demonstrates promising biological activity by effectively modulating inflammatory signaling pathways, making it a valuable tool in the study of rheumatoid arthritis and other inflammatory conditions. This compound enables researchers to delve into the mechanisms of p38α inhibition and its potential therapeutic applications in chronic inflammatory diseases. -
p38 Inhibitor
PS-166276 is a potent inhibitor of p38 mitogen-activated protein kinase (MAPK). With an IC50 of 28 nM against p38 kinase, it demonstrates significant inhibitory effects while maintaining lower cytotoxicity. This reagent is valuable for research applications focusing on inflammation, cell signaling, and related therapeutic pathways involving p38 MAPK modulation. -
p38α Inhibitor
p38α Inhibitor 4 is a selective allosteric inhibitor targeting the p38α MAPK pathway, demonstrated by an IC50 value of 1.2 μM. This compound exhibits specificity for p38α, showing no activity against p38β, p38γ, and p38δ. p38α Inhibitor 4 is valuable for research exploring inflammatory responses, cell signaling pathways, and related disorders where p38α activity plays a critical role. -
p38 MAPK Inhibitor
Anti-inflammatory agent 7 is a selective p38 MAPK inhibitor that modulates the NF-κB/MAPK signaling pathway to inhibit proinflammatory cytokine production. This reagent demonstrates significant anti-inflammatory activity in LPS-treated RAW 264.7 cells and in in vivo models, making it a valuable tool for studying inflammatory responses and developing therapeutic strategies for related diseases. -
p38 Alpha Kinase Inhibitor
CP-944629 is a potent inhibitor of p38 alpha kinase with an IC50 value of 3.2 μM. This compound effectively modulates the p38 MAPK signaling pathway, making it valuable in the study of chronic inflammatory diseases. Its ability to inhibit p38 alpha kinase may provide insights into therapeutic strategies for conditions driven by excessive inflammation. -
P38 MAPK Inhibitor
NJK14047 is a selective inhibitor of p38 MAPK, a key signaling pathway involved in inflammatory responses. This compound effectively inhibits the differentiation of naive T-cells into Th1 and Th17 cells, thus modulating immune responses. NJK14047 has demonstrated therapeutic potential in preclinical models, ameliorating collagen-induced rheumatoid arthritis and imiquimod-induced psoriasis in mice, making it a valuable tool for research into inflammatory diseases and immune regulation. -
p38 Inhibitor
p38-α MAPK-IN-10 is a potent inhibitor of p38α MAPK, exhibiting an IC50 value of 4 nM. This compound is utilized in research to investigate the role of p38α in inflammatory processes, cellular stress responses, and various pathological conditions. Its selective inhibition makes it an essential tool for studying signal transduction pathways and developing potential therapeutic strategies. -
p38 MAPK Inhibitor Negative Control
SB 202474 is a negative control compound designed for p38 MAPK inhibition studies. Unlike its active analog SB203580, SB 202474 does not inhibit p38 MAPK activity, making it an essential tool for validating experimental results in MAPK pathways. Additionally, it has been shown to suppress melanin synthesis induction, providing further applications in biochemical research related to pigment production. -
p38 Inhibitor
p38 Kinase Inhibitor 7 is a potent inhibitor of p38α with an IC50 value of 5.25 nM. This compound effectively reduces TNFα production in THP-1 cells, demonstrating an IC50 of 5.88 nM. p38 Kinase Inhibitor 7 is valuable for research focused on inflammation and related signaling pathways, making it a useful tool in cytokine modulation studies. -
p38 MAPK Inhibitor
SB-204900 is a selective inhibitor of p38 mitogen-activated protein kinase (MAPK). This compound exhibits significant inhibition of p38 MAPK phosphorylation, making it a valuable tool in the study of inflammatory signaling pathways. SB-204900 is primarily utilized in research focused on understanding the molecular mechanisms underlying inflammatory responses and developing potential therapeutic strategies for related conditions. -
p38α Inhibitor
FS-694 is a potent inhibitor of p38α, exhibiting an IC50 of 0.2 nM. This compound effectively suppresses TNFα release in human whole blood, with an IC50 value of 35.0 nM. FS-694 can be utilized in research aimed at understanding p38α signaling pathways and investigating inflammatory responses. -
p38 MAP Kinase Inhibitor
SC-68376 is a selective, reversible inhibitor of p38 MAP kinase, functioning through competitive inhibition of ATP binding. This compound exhibits significant biological activity in modulating inflammatory responses and cellular stress signaling pathways. SC-68376 is valuable for research applications related to inflammation, neurodegenerative diseases, and cancer, enabling the exploration of p38 MAP kinase's role in various pathological conditions. -
p38-α MAPK Inhibitor
p38-α MAPK-IN-9 is a highly potent inhibitor of the p38-α mitogen-activated protein kinase (MAPK), exhibiting a Ki value of 0.057 nM. This compound effectively inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor-alpha (TNFα) production in human peripheral blood mononuclear cells (hPBMCs), with an IC50 of 18 nM. p38-α MAPK-IN-9 is valuable for research applications focused on inflammatory signaling pathways and the study of cytokine modulation. -
p38 MAPK Inhibitor
p38 MAP Kinase Inhibitor VI is a selective inhibitor of p38 MAPK, exhibiting a moderate inhibition rate of 24%. This compound is instrumental in research focused on inflammation, apoptosis, and cellular stress responses. It can be utilized to explore the role of p38 MAPK in various pathological conditions and to develop therapeutic strategies targeting this signaling pathway. -
p38 Inhibitor
p38 MAP Kinase-IN-1 is a selective inhibitor of the p38 MAP kinase pathway, which plays a crucial role in mediating inflammation and immune responses. This compound is valuable for researchers investigating the mechanisms behind inflammatory diseases and autoimmune disorders. It can facilitate studies aimed at understanding p38's role in cellular signaling and its potential as a therapeutic target in inflammatory-related conditions. -
p38 MAPK Inhibitor
p38 MAPK-IN-6 is a selective p38 MAPK inhibitor that exhibits potential in modulating inflammatory pathways and stress responses. With a demonstrated inhibitory effect of 14% at a concentration of 10 μM, this compound serves as a valuable tool for studying p38 MAPK signaling in various cellular models. Its application extends to research in conditions associated with chronic inflammation and related diseases. -
p38 MAPK Inhibitor
AKP-001 is a selective inhibitor of p38 mitogen-activated protein kinase (p38 MAPK). This compound effectively reduces the production of pro-inflammatory cytokines, making it valuable for studying inflammatory processes. AKP-001 is particularly relevant for research focused on rheumatoid arthritis and inflammatory bowel disease, providing insights into potential therapeutic interventions for these conditions. -
BRD 4/p38α/BRDT Inhibitor
SB-284851-BT is a selective inhibitor of BRD4, p38α, and BRDT. It effectively inhibits BRD4-BD1 with an IC50 of 1.7 µM, p38α with a Kd of 0.47 nM, and exhibits additional inhibitory activity against BRDT and BRD4 with IC50 values of 18 µM and 3.7 µM, respectively. SB-284851-BT significantly reduces IL-8 production through p38α inhibition and downregulates crucial oncogenic pathways such as c-Myc and NF-κB via BRD4 inhibition. This compound has potential applications in cancer research and therapeutic development targeting cellular signaling pathways. -
p38 MAPK Inhibitor, JNK Inhibitor
HE4-1 leech peptide is a selective inhibitor of p38 MAPK and c-Jun N-terminal kinase (JNK). It effectively suppresses macrophage migration while maintaining normal macrophage immunological functions, such as phagocytosis, lysozyme activity, and the expression of various inflammatory factors. This peptide is primarily utilized in research focused on atherosclerosis and inflammation-related studies. -
TOPK-p38/JNK Inhibitor
TOPK-p38/JNK-IN-1 is an orally active inhibitor targeting the TOPK-p38/JNK signaling pathway, exhibiting an IC50 value of 2.14 µM for nitric oxide production. This compound demonstrates significant anti-inflammatory activity by inhibiting the phosphorylation of downstream proteins while preventing degradation of TOPK. Research applications include studies on inflammatory processes and cellular signaling mechanisms in various disease models. -
JNK3/p38 Inhibitor
SR-3737 is a potent inhibitor of JNK3 and p38 mitogen-activated protein kinases, with IC50 values of 12 nM and 3 nM, respectively. This compound exhibits significant biological activity by modulating pathways involved in stress responses and inflammation. SR-3737 is useful in research applications focusing on neuronal signaling, cytokine production, and the molecular mechanisms underlying various neurodegenerative diseases. -
p38 Inhibitor
p38 Kinase Inhibitor 8 is a selective inhibitor of p38β and JNK2α2, demonstrating IC50 values of 6.3 nM and 53.6 nM, respectively. This compound has shown significant anti-inflammatory properties in models of collagen-induced arthritis in rats, making it a valuable tool for research into inflammatory diseases and related signaling pathways. Its orally active nature enhances its practicality for in vivo studies. -
p38 MAPK Inhibitor
Gossypetin is a hexahydroxylated flavonoid that primarily targets the p38 MAPK signaling pathway by inhibiting mitogen-activated protein kinase kinases MKK3 and MKK6. This inhibition effectively attenuates the MKK3/6-p38 signaling pathway, leading to multiple pharmacological effects, including antioxidant, antibacterial, and anticancer activities. Gossypetin is of interest in research exploring therapeutic applications against various diseases mediated by p38 MAPK signaling dysregulation. -
p38 Inhibitor
N-Acetylmuramic acid is a key component of the bacterial cell wall peptidoglycan, targeting the p38 MAPK signaling pathway. It plays a critical role in maintaining cell shape and integrity in bacterial species, particularly Bacteroides forsythus, while also inhibiting spore germination through the inhibition of hexosaminidase and core enzymes. Additionally, N-acetylmuramic acid exhibits significant anti-inflammatory activity, making it a valuable reagent in studies of cellular proliferation and inflammatory responses. This compound is noted for its oral bioactivity. -
NF-κB p65 Inhibitor, p38 MAPK Inhibitor
PSMα3 is an inhibitor of NF-κB p65 and p38 MAPK, playing a significant role in modulating inflammatory pathways. This compound forms membrane pores and interacts with the human insulin B chain, inhibiting insulin aggregation and contributing to cytotoxic effects through α-type amyloid-like fibril formation. PSMα3 is valuable for research on spondyloarthritis, rheumatoid arthritis, insulin-derived amyloidosis, and infections caused by Staphylococcus aureus. -
p38 MAPK Inhibitor
Bisabolangelone is a potent inhibitor of the p38 MAPK pathway. Isolated from the roots of Osterici Radix, this sesquiterpene derivative demonstrates significant anti-inflammatory activity by inhibiting LPS-stimulated inflammation through the blockade of the NF-kappaB and MAPK signaling pathways in macrophages. Additionally, Bisabolangelone exhibits anti-ulcer activities, making it a valuable tool in studies related to inflammation and gastrointestinal disorders. -
p38 MAPK Inhibitor
p38 MAP Kinase Inhibitor III is a potent inhibitor of p38 MAPK, with an IC50 value of 0.9 μM. This compound also effectively reduces the release of pro-inflammatory cytokines, specifically IL-1β and TNF-α, with IC50 values of 0.37 μM and 0.044 μM, respectively. p38 MAP Kinase Inhibitor III is valuable for research in inflammation, signaling pathways, and related therapeutic applications. -
p38α Inhibitor
Emprumapimod is a selective inhibitor of p38α MAPK that exhibits potent oral activity. By directly inhibiting LPS-induced IL-6 production in RPMI-8226 cells (IC50=100 pM), it presents significant anti-inflammatory properties. This compound is applicable in research studies focused on dilated cardiomyopathy and acute inflammatory pain, making it a valuable tool for elucidating the role of p38α in various inflammatory conditions. -
p38α MAPK Inhibitor
p38α Inhibitor 2 is a highly selective inhibitor of the p38α mitogen-activated protein kinase (MAPK), exhibiting a pIC50 value of 9.6. This compound demonstrates potent inhibition of the hERG ion channel with an IC50 of 27 μM. Additionally, p38α Inhibitor 2 shows an excellent selectivity profile, demonstrating less than 30% inhibition across a panel of 51 protein kinases at a concentration of 10 μM, indicating its potential utility in various biological research applications focused on inflammation and stress responses. -
p38α Inhibitor
SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, exhibiting an IC50 of 3.2 nM. This compound also demonstrates weak inhibition of p38β MAPK with an IC50 of 122 nM. SD-169 has been shown to impede the development and progression of diabetes by inhibiting T cell infiltration and activation, making it valuable for research in immunology and metabolic disease pathways. -
p38 MAPK Inhibitor
p38 MAPK-IN-4 is a selective inhibitor of p38 mitogen-activated protein kinase (MAPK) with an IC50 of 35 nM. This compound modulates the p38 MAPK signaling pathway, which is critical in cellular responses to stress and inflammation. It is suitable for research applications investigating inflammatory diseases, cancer, and other conditions associated with p38 MAPK activity. -
p38α MAPK Inhibitor
p38 MAP Kinase Inhibitor IV is a selective ATP-competitive inhibitor targeting p38α MAPK, exhibiting IC50 values of 0.13 μM and 0.55 μM for p38α and p38β MAPK, respectively. This compound plays a crucial role in modulating cellular responses to stress and inflammation by inhibiting the p38 MAPK signaling pathway. It is utilized in research applications focused on therapeutic interventions for inflammatory diseases and various cancer models. -
p38 MAPK Inhibitor, coumarin, glucoside
Esculin sesquihydrate is a coumarin glucoside that serves as an inhibitor of p38 MAPK. This compound has demonstrated significant biological activity in ameliorating cognitive impairment associated with experimental diabetic nephropathy. Additionally, esculin sesquihydrate exhibits antioxidant and anti-inflammatory properties, primarily through modulation of the MAPK signaling pathway, making it valuable for research in diabetes-related complications and inflammation studies. -
p38 MAPK Inhibitor
PF-03715455 is a selective p38 MAPK inhibitor with significant potency, demonstrating IC50 values of 0.88 nM for p38α and 23 nM for p38β. This compound effectively inhibits LPS-induced TNFα production in human whole blood, with an IC50 of 1.7 nM. PF-03715455 has potential applications in research focusing on chronic obstructive pulmonary disease (COPD) and inflammation-related pathways. -
DDR/p38 Inhibitor
SR-302 is a selective DDR/p38 inhibitor that exhibits potent biological activity with IC50 values of 0.125 μM for p38α, 0.023 μM for DDR1, and 0.018 μM for DDR2. This compound is valuable for investigating fibrotic disorders, including renal and pulmonary fibrosis, atherosclerosis, and various types of cancer. SR-302 serves as a key tool for elucidating the roles of DDR and p38 signaling pathways in disease progression and therapeutic intervention. -
p38/MAPK Inhibitor
LX-3 is a selective inhibitor of the p38 MAPK signaling pathway. It effectively modulates gene expression by reactivating silenced EGFP reporter genes associated with DNA methylation, including TNF, EGR1, LY6K, and ISG20. This reagent is valuable for studies investigating the roles of p38 MAPK in cellular processes and the impact of DNA methylation on gene regulation.
